Company Overview of Actis Capital, LLP
Actis Capital, LLP is a private equity and venture capital firm specializing in expansion capital, PIPEs, replacement capital, acquisitions, industry consolidation, management buyouts/buyins, leveraged buyouts, going private transactions, privatizations, property development finance, and mezzanine finance investments in emerging and growing companies. It does not invest in seed and startup stage; and military and gambling. The firm primarily seeks to invest in companies operating in consumer including education, food and beverage, home and personal care, restaurants and retail; financial services including banking, consumer credit, financial services distribution and payments; healthcare inc...
2 More London Riverside
London, SE1 2JT
Founded in 2004
44 20 7234 5000
44 20 7234 5010
Key Executives for Actis Capital, LLP
Director and Head of Operations
Partner and General Counsel
Partner and Co-Head of Energy
Compensation as of Fiscal Year 2014.
Actis Capital, LLP Key Developments
Carlyle Reportedly Set To Acquire Destimoney From NSR
Dec 3 14
The Carlyle Group LP (NasdaqGS:CG) has come up as a frontrunner in race to acquire Destimoney Enterprises Private Limited from New Silk Route (NSR). According to the sources, the potential transaction is valued at INR 12 billion. The news report mentioned that formal announcement is due in the coming weeks. An official added, “Carlyle will most certainly buyout NSR from the housing finance JV. Last moment discussions are still on for the residual businesses like broking, distribution and I banking, which are much smaller in scale and size.” The news report mentioned that NSR and Carlyle's spokespersons declined to comment on the matter. Since 2013, NSR has been trying to monetize Destimoney investment and has had discussions with firms like General Atlantic LLC, Actis Capital, LLP, ChrysCapital and GIC Pte. Ltd. However, talks with most fell through.
ChrysCapital Reportedly In Talks To Sell Mankind Pharma
Oct 14 14
ChrysCapital intends to sell its stake in Mankind Pharma Limited. ChrysCapital is holding talks to sell its 11% stake in Mankind Pharma. The potential buyers are all PE firms, including Temasek Holdings (Private) Limited, General Atlantic LLC, Actis Capital, LLP and Advent International Corporation. ChrysCapital hopes to fetch over $200 million for its 11% holding. Financial Services Monitor Worldwide added that Ramesh Juneja, Chief Executive Officer of Mankind, said in an email response: Regarding ChrysCapital seeking exit from Mankind you may directly speak with them because it is entirely their decision. ChrysCapital spokesperson Sanjiv Kaul declined comment.
Chryscapital-GIC Team Emerges As Front-Runner In Race To Buy Destimoney
Jun 16 14
A consortium of ChrysCapital and GIC Pte. Ltd. has emerged as the front-runner to purchase New Silk Route's (NSR) 100% stake in Destimoney Enterprises Private Limited. "They seem to have gained a clear edge over rival bidders", said a person directly involved with the transaction. The deal may value the company between INR 10 billion and INR 11 billion. NSR has mandated Morgan Stanley to sell Destimoney. Actis Capital, LLP and General Atlantic LLC had also participated in the bidding. While New Silk Route's Chief Executive Officer Parag Saxena did not reply to email questions on the subject, Destimoney's Managing Director and Chief Executive Officer Sudip Bandyopadhay declined comment.
Similar Private Companies By Industry
Recent Private Companies Transactions